Life science analytics market seen reaching $118.6B by 2035

The global life science analytics market is projected to grow from $47.5 billion in 2026 to $118.6 billion by 2035, driven by real-world evidence mandates, cloud migration and generative AI adoption. North America leads today, while Asia-Pacific is expected to be the fastest-growing region through the forecast period.

Why it matters: - The market is moving from reporting tools to predictive and prescriptive systems that can help life sciences companies anticipate adverse events, improve patient stratification and speed development decisions. - Demand is rising as biopharma spending grows and payers push for value-based reimbursement tied to real-world outcomes. - The shift affects drug discovery, clinical development, pharmacovigilance, commercial planning and regulatory submissions.

What happened: - Market Research Future estimated the global life science analytics market at $42.9 billion in 2025. - The market is projected to reach $47.5 billion in 2026 and $118.6 billion by 2035. - The forecast implies a 10.7% compound annual growth rate from 2026 to 2035. - A free sample is available here. - Detailed research is available here.

The details: - Regulatory acceptance of real-world evidence and analytics-driven submissions is accelerating adoption. - Cloud and SaaS migration is replacing legacy systems across life-science data environments. - Generative AI is being integrated into drug discovery, clinical development, pharmacovigilance and commercial decision-making. - North America holds a 44.0% market share. - Asia-Pacific is the fastest-growing region, with a 13.8% CAGR through 2035. - Descriptive analytics led product types with a 48.0% revenue share in 2025. - Predictive analytics reached $12.45 billion in 2025. - Prescriptive analytics is the fastest-growing product type, with a 14.8% CAGR through 2035. - Services accounted for 59.0% of component share in 2025. - Software platforms are growing fastest, at a 15.1% CAGR through 2035. - On-premise deployment held a 69.0% share in 2025. - Cloud-based deployment is expanding fastest, at a 14.9% CAGR through 2035. - Research and development was the largest application segment, with a 44.5% share in 2025. - Pharmacovigilance was valued at $7.30 billion in 2025. - Sales, marketing and market access is the fastest-growing application area, with a 15.1% CAGR through 2035. - Pharmaceutical and biotechnology companies were the largest end-user group, with a 64.0% share in 2025. - Medical device companies are the fastest-growing end-user segment, with a 15.8% CAGR through 2035. - Contract research organizations generated $4.50 billion in 2025. - Illumina introduced Illumina Connected Multiomics in January 2026. - Ibex Medical Analytics expanded its biopharma platform into late-stage biomarker development in January 2026. - SAS introduced SAS Clinical Acceleration in November 2025.

Between the lines: - The market is being shaped by compliance, not just efficiency. - Analytics is becoming a strategic requirement for evidence generation, not a back-office function. - Cloud-native and AI-enabled tools are gaining ground because they can handle larger, more complex and more connected data streams. - The competitive field remains fragmented outside the top tier, leaving room for specialized analytics and AI vendors.

What's next: - By 2030, agentic AI could move life-science analytics toward decision-execution systems that automate case processing, signal detection and regulatory narrative generation. - Vendors are likely to consolidate separate tools for clinical, commercial and safety analytics into integrated platforms. - Regulatory convergence across FDA, EMA and PMDA frameworks could simplify multinational evidence generation and submission workflows. - The report identifies additional growth in South America and the Middle East and Africa as digital health and clinical-trial infrastructure expand.

The bottom line: - Life science analytics is shifting from a reporting market to an AI-enabled decision infrastructure market, with cloud deployment, regulatory demand and real-world evidence driving the next growth phase.